Join
Live feed
·
INSIDERFilingvia Quantisnow
CRISPR Therapeutics AG logo

Chief Executive Officer Kulkarni Samarth converted options into 13,250 shares and sold $1,006,580 worth of shares (18,568 units at $54.21), decreasing direct ownership by 3% to 189,973 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRSP (CRISPR Therapeutics AG) and more on Quantisnow.